28218-71-5

Basic information

• Product Name: 4,4-DIMETHOXY-TETRAHYDRO-4H-PYRAN
• Synonyms: 4,4-DIMETHOXY-TETRAHYDRO-4H-PYRAN;TETRAHYDRO-4H-PYRAN-4-ONE-DIMETHYL ACETAL;2H-Pyran, tetrahydro-4,4-dimethoxy-;4,4-DIMETHOXY-TETRAHYDRO-4H-PYRAN 97+%;Tetrahydro-2H-pyran-4-one dimethyl acetal;4,4-DIMETHOXY-TETRAHYDRO-4H-PYRAN FOR SY;tetrahydro-4,4-dimethoxy-2H-pyran;4,4-DIMETHOXYTETRAHYDRO-2H-PYRAN
• CAS NO: 28218-71-5
• Molecular Formula: C₇H₁₄O₃
• Molecular Weight: 146.18
• Mol File: 28218-71-5.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 172°C at 760 mmHg
• Flash Point: 53.9°C
• Appearance: /
• Density: 1.042 g/mL at 20 °C(lit.)
• Vapor Pressure: 1.81mmHg at 25°C
• Refractive Index: 1.431
• CAS DataBase Reference: 4,4-DIMETHOXY-TETRAHYDRO-4H-PYRAN(CAS DataBase Reference)
• NIST Chemistry Reference: 4,4-DIMETHOXY-TETRAHYDRO-4H-PYRAN(28218-71-5)
• EPA Substance Registry System: 4,4-DIMETHOXY-TETRAHYDRO-4H-PYRAN(28218-71-5)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 28218-71-5(Hazardous Substances Data)

Usage

General Description

4,4-Dimethoxy-tetrahydro-4H-pyran is a chemical compound which belongs to the class of organic compounds known as tetrahydrofurans. These are compounds containing a tetrahydrofuran ring, which is a five-membered saturated ring with four carbon atoms and one oxygen atom. 4,4-Dimethoxy-tetrahydro-4H-pyran is used in the food industry for its scent and flavor enhancing properties. It is also used in numerous chemical reactions in laboratories and industries due to its properties. The compound can potentially be hazardous as inhaling, consuming or touching it can lead to irritation in eyes, skin and respiratory system. It should be handled carefully under controlled conditions and in adherence to safety protocols.

InChI:InChI=1/C7H14O3/c1-8-7(9-2)3-5-10-6-4-7/h3-6H2,1-2H3

Upstream product

• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 67-56-1 methanol 
• 149-73-5 trimethyl orthoformate 
• 77-76-9 2,2-dimethoxy-propane 

Downstream Products

• 17327-22-9 4-methoxy-2,6-dihydropyran 
• 624734-19-6 3-fluorodihydro-2H-pyran-4(3H)-one 
• 1630906-37-4 (3R,4R)-3-fluorotetrahydro-2H-pyran-4-amine hydrochloride 
• 1395080-72-4 (3R,4R)-N-benzyl-3-fluorotetrahydro-2H-pyran-4-amine 
• 1630906-37-4 (3S,4S)-3-fluorotetrahydro-2H-pyran-4-amine hydrochloride 
• 1395080-71-3 (3R,4R)-N-benzyl-3-fluorotetrahydro-2H-pyran-4-amine 
• 1270077-00-3 6-(benzyloxy)-3-fluoro-N-((4-methoxytetrahydro-2H-pyran-4-yl)methyl)pyridin-2-amine 
• 1269755-10-3 (4-methoxytetrahydro-2H-pyran-4-yl)methanamine 
• 175982-78-2 1-(4-Methoxy-tetrahydro-pyran-4-yl)-ethanone 
• 175982-76-0 4-methoxytetrahydro-2H-pyran-4-carbaldehyde 

Relevant articles and documents

Synthesis of Functionalized Aliphatic Acid Esters via the Generation of Alkyl Radicals from Silylperoxyacetals

We describe a catalytic method for the synthesis of a variety of functionalized aliphatic acid esters using silylperoxyacetals, which are versatile alkyl radical precursors with a terminal ester moiety. In the presence of an appropriate transition-metal catalyst, the in situ generation of alkyl radicals and the subsequent bond-forming process proceeds smoothly to afford synthetically valuable aliphatic acid derivatives. The present method can be applied to the efficient synthesis of a pharmaceutically important 1,1-diarylalkane motif. In addition, a novel strategy for the synthesis of structurally diverse hydroxy acid derivatives via a C?O bond formation process that utilizes TEMPO has been developed.

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

3-(AMINOARYL)-PYRIDINE COMPOUNDS

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are pharmaceutical compositions containing these compounds and methods of treating a disease or condition mediated by CDK9 using these compounds and compositions.